Abbonarsi

No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes - 01/11/17

Doi : 10.1016/j.diabet.2008.05.010 
A. Godbout a, I. Hammana b, c, S. Potvin c, D. Mainville c, A. Rakel a, b, c, Y. Berthiaume a, c, d, J.-L. Chiasson a, b, c, d, e, L. Coderre a, b, c, f, R. Rabasa-Lhoret a, c, , e
a Endocrinology Division, Department of Medicine, centre hospitalier de l’université de Montréal, Montréal, Québec, Canada 
b Department of Nutrition, University of Montreal, Montreal, Quebec, Canada 
c Centre de recherche du centre hospitalier de l’université de Montréal, pavillon Masson, hôpital Hôtel-Dieu, 3850 Saint-Urbain Montréal, Québec H2W 1T7, Canada 
d Cystic Fibrosis Clinic, Pneumology Division, CHUM, Montreal, Quebec, Canada 
e Montreal Diabetes Research Center, Montreal, Quebec, Canada 
f Department of Medicine, University of Montreal, Montreal, Quebec, Canada 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Aim

Cystic fibrosis-related diabetes (CFRD) prevalence has increased dramatically with the improved life expectancy of patients with cystic fibrosis (CF). Glycated haemoglobin (HbA1c) is an important tool for monitoring blood glucose control but, unlike in type 1 and type 2 diabetes, a correlation between HbA1c, fructosamine and mean plasma glucose has not been clearly established in CF. This study aimed to examine the relationship between mean plasma glucose and HbA1c or fructosamine in stable patients with CFRD.

Methods

Fifteen type 1 diabetes and 13 CFRD patients (HbA1c<9.0%; no anaemia), matched for age and body mass index (BMI), provided 72 capillary blood glucose profiles taken 3days/month for three months. At the end of this time, HbA1c and fructosamine were measured. Mean plasma glucose was estimated using the Diabetes Control and Complications Trial (DCCT) conversion formula, and linear regressions carried out to establish its relationship with HbA1c and fructosamine.

Results

In type 1 diabetes patients, mean plasma glucose correlated significantly with HbA1c (r=0.68; P=0.005). In CFRD patients, no correlation was found between mean plasma glucose and HbA1c (r=0.24; P=0.460). Also, no association was found between mean plasma glucose, representing the month before blood sampling, and fructosamine in either group.

Conclusion

Unlike in type 1 diabetes, HbA1c did not correlate with mean plasma glucose in CFRD subjects. Thus, having a normal HbA1c may not be sufficient to indicate a low risk of diabetes complications in CFRD. Further studies are required to explain such a discrepancy.

Il testo completo di questo articolo è disponibile in PDF.

Résumé

But

La prévalence du diabète associé à la mucoviscidose (DbMV) a augmenté avec l’amélioration de la survie des patients atteints de mucoviscidose. Contrairement aux patients atteints de diabète type 1 ou 2, les corrélations entre l’hémoglobine glyquée (HbA1c), la fructosamine et la glycémie moyenne ne sont pas bien caractérisées chez les sujets avec DbMV. Cette étude décrit la relation entre la glycémie moyenne et l’HbA1c ou fructosamine dans un groupe de DbMV stable sur le plan médical.

Méthode

Quinze diabétiques type 1 (DT1) et 13 sujets DbMV ont été recrutés. Chaque patient a fourni 72 glycémies capillaires recueillies sur 3jours/mois durant trois mois. À la fin du trimestre, des prélèvements pour HbA1c et fructosamine ont été faits. La glycémie moyenne fut estimée à partir de la formule de conversion du Diabetes Complication and Control Trial (DCCT). Les relations entre la glycémie moyenne et HbA1c ou fructosamine ont été établies par régression linéaire.

Résultats

Pour les DT1, la glycémie moyenne corrèle de façon significative avec HbA1c (r=0,68 ; P=0,005). Pour les patients DbMV, aucune corrélation entre la glycémie moyenne et HbA1c n’a été démontrée (r=0,24 ; P=0,460). Pour les deux groupes, aucune relation n’a été établie entre la glycémie moyenne du mois précédant le prélèvement et la fructosamine.

Conclusion

Contrairement aux patients DT1, l’HbA1c n’est pas un bon reflet de la glycémie moyenne chez les sujets avec DbMV. Une valeur normale d’HbA1c pourrait être insuffisante comme indicateur d’un faible risque de complications. Des études sont nécessaires pour caractériser cette discordance.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Cystic fibrosis, Glycated haemoglobin, Diabetes

Mots clés : Mucoviscidose, Fibrose kystique, Diabète, Hémoglobine glyquée


Mappa


© 2008  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 34 - N° 6

P. 568-573 - dicembre 2008 Ritorno al numero
Articolo precedente Articolo precedente
  • Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients
  • B. Bouhanick, V. Bongard, J. Amar, S. Bousquel, B. Chamontin
| Articolo seguente Articolo seguente
  • Risk factors and management of diabetes in elderly French patients
  • J. Doucet, L. Druesne, C. Capet, E. Gréboval, I. Landrin, P. Moirot, G. Micaud

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.